Alabama decision could spur interest in Femasys, says JonesResearch

JonesResearch says the Alabama Supreme Court ruling this week that frozen embryos created through in vitro fertilization are “extrauterine children” and are protected under state law sets a precedent that could potentially impact the entire U.S. IVF industry. In light of this, the firm expects greater interest in IVF alternatives, including Femasys’ intratubal insemination device, FemaSeed. FemaSeed received FDA clearance in September 2023 and preparations for a commercial launch are underway, the analyst tells investors in a research note. JonesResearch thinks FemaSeed could address an unmet need in male factor infertility. It keeps a Buy rating on the shares with a $7 price target.